ECMO for COVID-19 vs Influenza A H1N1 Associated ARDS
InfluCOV_ECMO
Extracorporeal Membrane Oxygenation for COVID-19 and Influenza H1N1 Associated Acute Respiratory Distress Syndrome: a Multi-centre Retrospective Cohort Study
1 other identifier
observational
308
1 country
1
Brief Summary
Objective: Veno-venous ECMO has been used as a rescue therapy for patients with severe ARDS associated to influenza A H1N1 and COVID19 viral pneumonia. Little is known about outcome of these patients who required extracorporeal support. Research question: To compare outcome of patients who required VV ECMO for Covid19 and H1N1 associated ARDS
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2009
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 22, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
February 28, 2021
CompletedFirst Submitted
Initial submission to the registry
October 15, 2021
CompletedFirst Posted
Study publicly available on registry
October 18, 2021
CompletedOctober 18, 2021
October 1, 2021
11.5 years
October 15, 2021
October 15, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
All cause mortality on day 60 after ECMO initiation
60 days
Secondary Outcomes (9)
Hospital length of stay
90 days
ICU length of stay
90 days
Hospital mortality on day 90 after ECMO initiation
90 days
ECMO duration
90 days
ECMO associated hemorrhagic complications
60 days
- +4 more secondary outcomes
Study Arms (2)
COVID-19
H1N1
Eligibility Criteria
Patients who required VV ECMO for COVID-19 and influenza A H1N1 associated ARDS
You may qualify if:
- COVID-19 or influenza A H1N1 (suspected or confirmed) diagnosis
- Severe ARDS (according to Berlin Definition)
- VV ECMO
- Invasive mechanical ventilation through endotracheal tube or tracheostomy
You may not qualify if:
- Age\<18 years
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Turin - Azienda Ospedaliera Città della Salute e della Scienza di Torino
Turin, 10126, Italy
Related Publications (1)
Fanelli V, Giani M, Grasselli G, Mojoli F, Martucci G, Grazioli L, Alessandri F, Mongodi S, Sales G, Montrucchio G, Pizzi C, Richiardi L, Lorini L, Arcadipane A, Pesenti A, Foti G, Patroniti N, Brazzi L, Ranieri V. Extracorporeal membrane oxygenation for COVID-19 and influenza H1N1 associated acute respiratory distress syndrome: a multicenter retrospective cohort study. Crit Care. 2022 Feb 5;26(1):34. doi: 10.1186/s13054-022-03906-4.
PMID: 35123562DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD
Study Record Dates
First Submitted
October 15, 2021
First Posted
October 18, 2021
Study Start
August 22, 2009
Primary Completion
February 28, 2021
Study Completion
February 28, 2021
Last Updated
October 18, 2021
Record last verified: 2021-10
Data Sharing
- IPD Sharing
- Will not share